Document:

EX-10.5

 Exhibit 10.5 

CONFIDENTIAL 
 EMPLOYMENT
AGREEMENT 
 This Employment Agreement (this “Agreement”), dated as of 01/11/2021 is entered into by and between
Timothy Bensley (the “Executive”) and agilon health, inc., a Delaware corporation (the “Company”). 

W I T N E S S E T H: 

WHEREAS, Executive is currently employed as Chief Financial Officer of the Company; 

WHEREAS, in recognition of Executive’s role with the Company, the Company and Executive desire to enter into this Agreement in accordance
with the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein,
and intending to be legally bound hereby, the parties hereto agree as follows: 
 1. Nature of Employment 

Subject to Section 3, during the Term of Employment, the Company shall continue to employ the Executive, and the Executive agrees to
continue employment, as the Chief Financial Officer of the Company and in such position to continue to perform the duties and responsibilities commensurate with such position and as may be reasonably assigned to the Executive from time to time by
the Company. During the Term of Employment (as defined below), the Executive shall continue to report to the Chief Executive Officer of the Company (the “CEO”), or, if directed by the CEO, to another senior executive of the Company.

 2. Extent of Employment 

(a) During the Term of Employment, the Executive shall perform their obligations hereunder faithfully and to the best of their ability at the
place of employment provided in Section 2(d), as directed pursuant to Section 1, and shall abide by the policies from time to time established by the Company. 

(b) During the Term of Employment, the Executive shall devote all of their business time, energy and skill as may be reasonably necessary for
the performance of their duties, responsibilities and obligations hereunder (except for vacation periods and reasonable periods of illness or other incapacity). 

(c) As of the date hereof, the Executive does not have any ownership interests (other than ownership of less than 1% of the outstanding stock
of a publicly-traded company) or professional relationships with (whether as an employee, director, officer, consultant or advisor, and whether or not for compensation) or professional commitments to any person or entity (other than the Company and
its affiliates). 
 (d) During the Term of Employment, the principal place of Executive’s employment shall be in their home office or at
a location agreed to by CEO, with regular and frequent travel to all Company Offices where agilon health personnel are located. 

  
 1 

 3. Term of Employment; Termination 

(a) The “Term of Employment” shall continue until the Executive’s employment is terminated by the Company pursuant to
Section 3(b) or by the Executive pursuant to Section 3(c). 
 (b) Subject to the payments contemplated by Section 3(e), the
Executive’s employment may be terminated at any time by the Company: 
 (i) upon the death of the Executive; 

(ii) in the event that, because of physical or mental disability, the Executive is unable to perform, and does not perform, in the opinion of
the Company and as certified in writing by a competent medical physician selected by the mutual agreement of the Company and the Executive or their legal representative, their duties hereunder for a period of 180 days out of any 270-day period (“Disability”); 
 (iii) for Cause; or 

(iv) for any other reason or no reason, it being understood that no reason shall be required for termination of the Executive’s
employment. 
 The Executive acknowledges that nothing contained herein or otherwise stated by or on behalf of the Company modifies or
amends the right of the Company to terminate the Executive at any time, with or without Cause. Termination shall become effective upon death or the delivery by the Company to the Executive of notice specifying such termination and the reasons
therefor (i.e., Sections 3(b)(ii) – (iv)) subject to any requirement for advance notice and an opportunity to cure provided in this Agreement, if and to the extent applicable. 

(c) Subject to the payments contemplated by Section 3(e), the Executive’s employment may be terminated at any time by the Executive:

 (i) upon the death of the Executive; 

(ii) in the event of Disability; or 

(iii) for any other reason or no reason (a “Voluntary Termination”). 

(d) As used in this Agreement, “Cause” shall mean any of the following: 

(i) the Executive’s conviction of a crime involving moral turpitude, embezzlement, fraud, conversion of property or false statements or
other similar acts or any other felony; 
 (ii) the Executive’s gross negligence or continued willful failure (other than by reason of
death or Disability) to perform their material employment-related duties for the Company and its subsidiaries; 

  
 2 

 (iii) the Executive’s violation of a material provision of any written Company
subsidiary policy as in effect from time to time that has been communicated to the Executive, which violation is not cured within 30 days after the Company delivers written notice to the Executive that identifies and describes the alleged violation
in reasonable detail (the “Cure Period”); 
 (iv) the Executive’s material breach of any written agreement with
the Company or any of its affiliates to which the Executive is a party or by which the Executive is bound (including, but not limited to, this Agreement and an Employee Stock Option Agreement with the Company’s affiliate) which breach is not
cured within the Cure Period; provided that it shall be presumed that any material breach of the restrictive covenants contained in the Employee Stock Option Agreement is not capable of being cured for purposes of this definition of
“Cause”; 
 (v) the Executive’s breach of Section 2(c) or the last sentence of Section 8; or 

(vi) the Executive engaging in conduct that causes material harm to the name, reputation or business interests of the Company, or any of its
respective affiliates, including any affiliated independent physician association. 
 For purposes of this provision,
(A) no act or failure to act on the part of the Executive shall be considered “willful” unless it is done, or omitted to be done, by the Executive in bad faith or without reasonable belief that the Executive’s action or omission
was in the best interests of the Company and (B) any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the board of directors of the Company or upon the advice of counsel for the Company shall be
conclusively presumed to be done, or omitted to be done, by the Executive in good faith and in the best interests of the Company. 

A termination for Cause shall be deemed to include a determination by the Company within 90 days following the Executive’s
Voluntary Termination that circumstances existed prior to such termination for the Company to have terminated the Executive’s employment for Cause; provided that in such event the Executive shall first be provided with any applicable
cure rights to the extent available; and provided, further, that this sentence shall not apply to any circumstances actually known to the CEO 60 or more days prior to the date of such termination. 

(e) The Executive shall be entitled to certain payments upon termination of their employment, as follows: 

(i) In the event the Executive’s employment is terminated for any reason, the Executive shall be entitled to receive their Base Salary
through the effective date of termination, any accrued benefits unpaid as of the effective date of termination, any expense reimbursements related to expenses reimbursable hereunder that are incurred through the effective date of termination, and
other benefits required by law to be provided to their after termination of employment, in each case when paid according to the Company’s applicable lawful policies and standard practices and the lawful terms of this Agreement (the
“Base Termination Compensation”). 

  
 3 

 (ii) In the event the Executive’s employment is terminated by the Company for any
reason other than for Cause (and for the avoidance of doubt not death or Disability), then the Executive shall be entitled to (A) the Base Termination Compensation, and (B) severance pay equal to 12 months of the Executive’s base
salary and target annual bonus, at the rate in effect at the effective time of termination, to be paid in equal installments over 12 months on the Company’s normal payroll dates following the date of termination, except that the first
installment of such payment shall be paid on the 60th day following the termination date and shall include all installments that would have been paid if the release of claims referred to in
Section 3(h) had been effective at the date of termination and (Any payment of the Executive’s Base Salary after termination of their employment shall be made in accordance with the Company’s regular payroll practices. Other than
solely in connection with any vested employee stock options of a Company affiliate held by the Executive at the time of their termination of employment, there will be no additional amounts owing by the Company to the Executive from and after a
termination of the Executive’s employment of the nature contemplated by this clause (ii) of Section 3(e). 
 (iii) If the
Executive’s employment is terminated for Cause, then the Executive shall be entitled to the Base Termination Compensation. 
 (iv) If
the Executive’s employment is terminated due to a Voluntary Termination, then the Executive shall be entitled to the Base Termination Compensation. Other than solely in connection with any vested employee stock options of a Company affiliate
held by the Executive at the time of their termination of employment, there will be no additional amounts owing by the Company to the Executive from and after such termination of the nature contemplated by this clause (iv) of Section 3(e).

 (v) If the Executive’s employment is terminated due to the Executive’s death or Disability, then the Executive shall be entitled
to the Base Termination Compensation and, if terminated due to Disability, the Benefit Continuation. Other than solely in connection with any vested employee stock options of a Company affiliate held by the Executive at the time of their termination
of employment, there will be no additional amounts owing by the Company to the Executive from and after such termination of the nature contemplated by this clause (v) of Section 3(e). 

(f) Termination of the Executive’s employment will not terminate Sections 3(e) through 3(i) and 7 through 19, or any other provisions not
associated specifically with the Term of Employment. 
 (g) Any provision herein to the contrary notwithstanding, if, following their
termination of employment, the Executive materially breaches any restrictive covenant contained in the employee stock option agreement with the Company’s affiliate to which Executive is a party or, without the Company’s prior written
consent, competes with the business of the Company and its subsidiaries as then conducted, then from and after the date of such employment or engagement, the Company shall have no further payment or benefit obligations under Section 3(e)(ii).

 (h) In the event the Executive’s employment is terminated and the Company is obligated to make payments pursuant to
Section 3(e)(ii), other than the Base Termination Compensation, it shall be a condition to such payments that, within 30 days following the date of termination, the Executive enter into a general release of claims, substantially in the form
customarily used by the Company. 

  
 4 

 (i) Upon termination of the Executive’s employment for any reason, the Executive shall
be deemed to have resigned from all positions with the Company and its affiliates, including the Company, and, at the Company’s request, the Executive shall promptly deliver written evidence of such resignation. 

4. Compensation. The Company shall pay compensation to the Executive as follows: 

(a) Base Salary. During the Term of Employment, the Company shall pay to the Executive as base compensation for their services
hereunder, on the Company’s regular payroll dates, a base salary at a rate of not less than $500,000 per annum (“Base Salary”). 

(b) Annual Bonus 
 (i)
Generally. For each fiscal year during the Term of Employment, the Executive will be eligible for an annual bonus with a target payment equal to 75% of the Executive’s Base Salary based on the Executive’s achievement of pre-established performance goals and conditions determined by the Company on an annual basis in accordance with the annual bonus plan then applicable to senior management of the Company (the “Bonus
Plan”). Under the Bonus Plan, the actual amount of any bonus paid for any fiscal year shall be determined by the Company based on its assessment of the actual performance against such goals against the goals and conditions established for
the year. Any annual bonus payable to the Executive for a fiscal year shall be paid to the Executive not later than two and a half months following the end of such fiscal year to which the performance relates. It shall be a condition to the payment
of any annual bonus that the Executive remain employed through the last day of the applicable fiscal year. 
 5. Reimbursement of
Expenses. During the Term of Employment, the Company will promptly reimburse the Executive (or pay directly) for reasonable and documented travel, entertainment and other expenses reasonably incurred by the Executive in connection with the
performance of their duties hereunder and, in each case, in accordance with the policies, rules, customs and usages promulgated by the Company and in effect from time to time and applicable law. Any payments due under this Section 5 will be
payable in accordance with the Company’s usual payroll practices. 
 6. Benefits 

During the Term of Employment, the Executive shall be entitled to participate in and be covered by any insurance plan (including but not
limited to medical, dental, health, accident, hospitalization and disability), 401(k), profit sharing or other employee benefit plan of the Company, to the same extent and on substantially the same terms as such benefits are or may be provided by
the Company, at its sole discretion, from time to time to other members of the senior management of the Company, and in all circumstances in accordance with the policies, rules, customs and usages promulgated by the Company and in effect from time
to time. 

  
 5 

 7. Notice 

Any notice, request, demand or other communication required or permitted to be given under this Agreement shall be given in writing and if
delivered personally, or sent by certified or registered mail, return receipt requested, as follows (or to such other addressee or address as shall be set forth in a notice given in the same manner): 

(a) If to the Executive, to the Executive at the address most recently contained in the Company’s records (which the Executive shall
update as necessary) 
 (b) If to the Company: 

agilon health, inc. 
 1 World
Trade Center, Suite 2050 
 Long Beach, CA 90831 

Attention: CEO 
 with a
copy to (which shall not constitute notice): 
 Debevoise & Plimpton 

919 Third Avenue 
 New York, NY
10022 
 Attention: Meir Katz, Esq. 

Fax: (212) 521-7615 

Any such notices shall be deemed to be given on the date personally delivered or such return receipt is issued. 

8. Executive’s Representation 

The Executive hereby represents and warrants to the Company that the Executive has carefully reviewed this Agreement and has consulted with
such advisors as the Executive considers appropriate in connection with this Agreement, and is not subject to any covenants, agreements or restrictions, including without limitation any covenants, agreements or restrictions arising out of the
Executive’s prior employment, which would be breached or violated by Executive’s execution of this Agreement or by the Executive’s performance of their duties hereunder. In addition, the Executive hereby represents, warrants and
covenants to the Company that, as of the date hereof their does not have and during the Term of Employment (without the Company’s prior approval) their will not have any professional relationships with (whether as an employee, director,
officer, consultant or advisor, and whether or not for compensation) or commitments to any individual or entity (other than the Company) that operates or conducts (or, to the Executive’s knowledge, intends to operate or conduct) any business of
the types in which the Company, or any of its subsidiaries or affiliated independent physician associations is engaged. 

  
 6 

 9. Other Matters 

The Executive agrees and acknowledges that the obligations owed to the Executive under this Agreement are solely the obligations of the
Company, and that none of the stockholders, directors, officers, affiliates, representatives, agents or lenders of or to Company or any of its affiliates will have any obligations or liabilities in respect of this Agreement and the subject matter
hereof, to the extent allowed by law. 
 10. Partial Invalidity; Severability 

In case any one or more of the provisions or parts of a provision contained in this Agreement shall, for any reason, be held to be invalid,
illegal or unenforceable in any respect in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Agreement or any other jurisdiction, but this Agreement shall be
reformed and construed in any such jurisdiction as if such invalid or illegal or unenforceable provision or part of a provision had never been contained herein and such provision or part shall be reformed so that it would be valid, legal and
enforceable to the maximum extent permitted in such jurisdiction. 
 11. Waiver of Breach; Specific Performance 

The waiver by the Company or the Executive of a breach of any provision of this Agreement by the other party shall not operate or be construed
as a waiver of any other breach of any other party. Each of the parties to this Agreement will be entitled to enforce its respective rights under this Agreement and to exercise all other rights existing in its favor. In the event either party takes
legal action to enforce any of the terms or provisions of this Agreement, the nonprevailing party shall pay the successful party’s costs and expenses, including but not limited to, attorneys’ fees, incurred in such action. 

12. Assignment 
 Neither
the Executive, on the one hand, nor the Company, on the other hand, may assign, transfer, pledge, hypothecate, encumber or otherwise dispose of this Agreement or any of their or its respective rights or obligations hereunder, without the prior
written consent of the other, provided that the Company may assign its rights and obligations under this Agreement to another wholly-owned subsidiary of Parent that employs members of agilon health’s senior management. 

13. Amendment; Entire Agreement 

This Agreement may not be changed orally but only by an agreement in writing agreed to by the party against whom enforcement of any waiver,
change, modification, extension or discharge is sought. This Agreement embodies the entire agreement and understanding of the parties hereto in respect of the subject matter of this Agreement, and supersedes and replaces all prior agreements,
understandings and commitments with respect to such subject matter. 

  
 7 

 14. Governing Law; Choice of Forum 

THIS AGREEMENT SHALL BE GOVERNED BY, CONSTRUED, APPLIED AND ENFORCED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF DELAWARE. IN THE
EVENT ANY PARTY TO THIS AGREEMENT COMMENCES ANY LITIGATION, PROCEEDING OR OTHER LEGAL ACTION IN CONNECTION WITH OR RELATING TO THIS AGREEMENT, ANY RELATED AGREEMENT OR ANY MATTERS DESCRIBED OR CONTEMPLATED HEREIN OR THEREIN, THE PARTIES TO THIS
AGREEMENT HEREBY (1) AGREE UNDER ALL CIRCUMSTANCES ABSOLUTELY AND IRREVOCABLY TO INSTITUTE ANY LITIGATION, PROCEEDING OR OTHER LEGAL ACTION IN A COURT OF COMPETENT JURISDICTION LOCATED WITHIN THE CENTRAL DISTRICT OF CALIFORNIA, WHETHER A STATE
OR FEDERAL COURT; (2) AGREE THAT IN THE EVENT OF ANY SUCH LITIGATION, PROCEEDING OR ACTION, SUCH PARTIES WILL CONSENT AND SUBMIT TO THE PERSONAL JURISDICTION OF ANY SUCH COURT DESCRIBED IN CLAUSE (1) OF THIS SECTION AND TO SERVICE OF
PROCESS UPON THEM IN ACCORDANCE WITH THE RULES AND STATUTES GOVERNING SERVICE OF PROCESS (IT BEING UNDERSTOOD THAT NOTHING IN THIS SECTION SHALL BE DEEMED TO PREVENT ANY PARTY FROM SEEKING TO REMOVE ANY ACTION TO A FEDERAL COURT IN THE CENTRAL
DISTRICT OF CALIFORNIA); (3) IRREVOCABLY CONSENT TO THE SERVICE OF ANY AND ALL PROCESS IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT TO SUCH PARTY AT SUCH PARTY’S ADDRESS SPECIFIED IN SECTION 7; (4) AGREE TO
WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY OBJECTION THAT THEY MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH LITIGATION, PROCEEDING OR ACTION IN ANY SUCH COURT OR THAT ANY SUCH LITIGATION, PROCEEDING OR ACTION WAS BROUGHT IN ANY
INCONVENIENT FORUM; AND (5) AGREE, AFTER CONSULTATION WITH COUNSEL, TO WAIVE ANY RIGHTS TO A JURY TRIAL TO RESOLVE ANY DISPUTES OR CLAIMS RELATING TO THIS AGREEMENT. THE CHOICE OF FORUM SET FORTH IN THIS SECTION 14 SHALL NOT BE DEEMED TO
PRECLUDE THE ENFORCEMENT OF ANY ACTION UNDER THIS AGREEMENT IN ANY OTHER JURISDICTION. 
 15. Further Action 

The Executive and the Company agree to perform any further acts and to execute and deliver any documents which may be reasonable to carry out
the provisions hereof. 
 16. Counterparts 

This Agreement may be executed in counterparts, including facsimiles thereof, each of which shall be deemed an original, but all of which
together shall constitute one and the same agreement. 
 17. Payments by Subsidiaries 

The Executive acknowledges that one or more payments hereunder may be paid by one or more of the Company’s subsidiaries, and the Executive
agrees that any such payment made by such subsidiary shall satisfy the obligations of the Company hereunder with respect to (but only to the extent of) such payment. 

  
 8 

 18. Tax Matters 

The Executive acknowledges that the payments and benefits provided under the terms of this Agreement shall constitute taxable income to the
extent provided in the applicable provisions of the United States Internal Revenue Code of 1986, as amended, and any successor thereto and applicable regulations thereunder (the “Code”) and other applicable tax laws. Moreover, the
Executive understands and acknowledges that the Company have not provided any advice regarding their tax liability resulting from this Agreement and that their has been advised to consult with their personal tax advisor or legal counsel as to the
taxability of the payments and benefits provided under this Agreement. The Executive shall be solely responsible for taxes imposed on them by reason of any payments or benefits provided under this Agreement and all such payments and benefits shall
be subject to applicable federal, state, local and foreign withholding requirements. All payments to be made or benefits to be provided to the Executive pursuant to this Agreement shall be made net of all applicable income and employment taxes
required to be withheld from such payments pursuant to any applicable law or regulation. 
 19. Applicability of
Section 409A of the Code 
 To the extent that any reimbursement, fringe benefit or other, similar plan or arrangement
in which the Executive participates during the term of the Executive’s employment under this Agreement or thereafter provides for a “deferral of compensation” within the meaning of Section 409A of the Code, (i) the right to
reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount eligible for reimbursement or payment under such plan or arrangement in one calendar
year may not affect the amount eligible for reimbursement or payment in any other calendar year (except that a plan providing medical or health benefits may impose a generally applicable limit on the amount that may be reimbursed or paid), (iii)
subject to any shorter time periods provided in any expense reimbursement policy of the Company, any reimbursement or payment of an expense under such plan or arrangement must be made on or before the last day of the calendar year following the
calendar year in which the expense was incurred and (iv) the reimbursements shall be made pursuant to objectively determinable and nondiscretionary Company policies and procedures regarding such reimbursement of expenses. In addition, with
respect to any payments or benefits subject to Section 409A of the Code, reference to the Executive’s “termination of employment” (and corollary terms) with the Company shall be construed to refer to the Executive’s
“separation from service” (as determined under Treas. Reg. Section 1.409A-1(h), as uniformly applied by the Company) with the Company. Whenever a provision under this Agreement specifies a
payment period with reference to a number of days, the actual date of payment within the specified period shall be within the sole discretion of the Company. The Executive’s right to receive any installment payments hereunder shall, for
purposes of Section 409A, be treated as a right to receive a series of separate and distinct payments. If the timing of the Executive’s execution of a general release of claims pursuant to Section 3(h) could impact the calendar year
in which any payment under this Agreement that is subject to Section 409A of the Code will be made, such payment will be made in the later calendar year. 

  
 9 

 Notwithstanding anything to the contrary in this Agreement, if the Executive is a
“specified employee” within the meaning of Section 409A of the Code at the time of the Executive’s separation from service (other than due to death), then any payment under this Agreement that is subject to Section 409A of
the Code and that is payable by reason of the Executive’s separation from service within the first six months following the Executive’s separation from service will become payable on the first payroll date that occurs on or after the date
six months and one day following the date of the Executive’s separation from service. All subsequent related payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding
anything herein to the contrary, if the Executive dies following the Executive’s separation from service, but prior to the six month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be
payable in a lump sum as soon as administratively practicable after the date of the Executive’s death and all other related payments will be payable in accordance with the payment schedule applicable to each payment or benefit. 

The foregoing provisions are intended to comply with the requirements of Section 409A of the Code so that none of the severance payments
and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A of the Code, and, if any ambiguity is found herein with respect to such payments or benefits, any such ambiguities will be interpreted to so
comply. If any payment or benefits subject to Section 409A of the Code could be construed not to comply with Section 409A of the Code, the Company and the Executive agree to work together in good faith to consider amendments to this
Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to the Executive under Section 409A of the Code. 

[Signature Page Follows] 

  
 10 

 IN WITNESS WHEREOF, this Agreement has been executed as of the date first written above.

  

	
	EXECUTIVE
	
	 /s/ Tim Bensley

	Name: Tim Bensley
	
	AGILON HEALTH, INC.
	
	 /s/ Steve Sell

	Name: Steve Sell
	Title: Chief Executive Officer

  
 11EX-10.6

 *Certain identified information has been excluded because it is both not material 

and is the type that the registrant treats as private or confidential.* 

Exhibit 10.6 

CONFIDENTIAL 
 SEPARATION
AGREEMENT AND GENERAL RELEASE OF CLAIMS 
 This SEPARATION AGREEMENT AND GENERAL RELEASE (the “Agreement”), dated as of
May 22, 2020, is entered into by and among Agilon Health Holdings, Inc. (the “Company”), the undersigned, Ronald J. Kuerbitz, and, solely for purposes of Sections 4 and 5 below, Agilon Health Topco, Inc., the indirect
parent of the Company (“Topco”), and CD&R Vector Holdings, L.P., Topco’s majority investor (the “CD&R Investor”). 

WHEREAS, the undersigned’s employment with the Company and its subsidiaries and affiliates (together with Topco, the “Company
Group”) will be terminated by the Company Group without “cause” effective June 1, 2020 (the “Separation Date”) and, as of the date hereof, he will cease to be a member of the Board of Directors of Topco (the
“Board”): 
 WHEREAS, the Company has agreed to provide the undersigned with specified separation pay and benefits,
including treatment of his equity interests, subject to, among other things, his execution, delivery and non-revocation of a general release of claims; and 

WHEREAS, as of the date hereof, the undersigned owns 15,000 shares of Topco common stock (the “Topco Shares”), subject to the
terms and conditions of his Employee Stock Subscription Agreement (the “Subscription Agreement”), including repurchase rights over the Topco Shares following his termination of employment; 

WHEREAS, as of the date hereof the undersigned has 51,000 Base Options (as defined in his Employee Stock Option Agreement (the “Option
Agreement”)), all of which will be vested, subject to the Separation Benefit Conditions (as defined below), as of the Separation Date, and 33,000 Upside Options (as defined therein), all of which will be unvested as of the Separation Date,
subject to the terms and conditions of the Option Agreement; 
 WHEREAS, pursuant to Section 3(b) of the Option Agreement, the
undersigned would have 90 days following the Separation Date to exercise all of his vested Base Options, absent the extension of the exercise period provided herein, and all of his Upside Options, which will be unvested as of the Separation Date,
would be forfeited. 
 NOW, THEREFORE, in consideration of the promises set forth herein, and for other good and valuable consideration, the
receipt and sufficiency whereof is hereby acknowledged, the undersigned hereby agrees as follows: 
 1.    Release of
Claims. In consideration of the payments and benefits to which I am entitled under my Employment Agreement, dated as of December 9, 2016 (the “Employment Agreement”), and Option Agreement and as provided in Sections 2, 4, 5
and 6 below, I hereby waive and release and forever discharge the Company Group (including Topco), Clayton, Dubilier & Rice, LLC and its affiliated investment funds, and those entities which hold a direct and/or indirect interest in the
Company and which serve as the general partner or managing member of any such vehicles or of the general partner or managing members of such vehicles, 

 
and their respective affiliates, and all of the respective past and present officers, directors, employees, agents, representatives, stockholders, members and partners of the foregoing and any
and all employee pension benefit or welfare benefit plans of the Company Group, each in his, her or its capacity as such, and each of them, separately and collectively (collectively, “Releasees”), from any and all existing claims,
charges, complaints, liens, demands, causes of action, obligations, damages and liabilities, known or unknown, suspected or unsuspected, whether or not mature or ripe, that I ever had and now have against any Releasee, including, but not limited to,
claims and causes of action arising out of or in any way related to my employment with or separation from the Company Group, to any services performed for any member of the Company Group, to any status, term or condition in such employment or
relationship, or to any physical or mental harm or distress from such employment or non-employment or claim to any hire, rehire or future employment of any kind by any member of the Company Group, all to the
extent allowed by applicable law. This release of claims includes, but is not limited to, claims based on express or implied contract, compensation plans, covenants of good faith and fair dealing, wrongful discharge, claims for discrimination,
harassment and retaliation, violation of public policy, tort or common law, whistleblower or retaliation claims; and claims for additional compensation or damages or attorneys’ fees or claims under federal, state, and local laws, regulations
and ordinances, including, but not limited to, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the Worker Adjustment and Retraining Notification
Act (“WARN”), or equivalent state WARN act, the Employee Retirement Income Security Act (“ERISA”), and the Sarbanes-Oxley Act of 2002. 

I understand that this release of claims includes a release of all known and unknown claims through the date on which this release of claims
becomes irrevocable (the “Effective Release Date”). 
 I further agree, promise, and covenant that, to the maximum extent
permitted by law, neither I, nor any person, organization, or other entity acting on my behalf has filed or will file, charge, claim, sue, or cause or permit to be filed, charged, or claimed, any action for damages or other relief (including
injunctive, declaratory, monetary, or other relief against any of the Releasees involving any matter occurring in the past, or involving or based upon any claims, demands, causes of action, obligations, damages, or liabilities, in each case which
are subject to this release of claims. All Releasees shall be deemed to be third party beneficiaries of this Agreement to the same extent as if they were signatories hereto. 

Notwithstanding the foregoing, this release of claims will not prohibit me from filing a charge of discrimination with the National Labor
Relations Board, the Equal Employment Opportunity Commission (“EEOC”) or an equivalent state civil rights agency, but I agree and understand that I am waiving my right to monetary compensation thereby if any such agency elects to pursue a
claim on my behalf. Further, nothing in this release of claims shall be construed to waive any right that is not subject to waiver by private agreement under federal, state or local employment or other laws, such as claims for workers’
compensation or unemployment benefits or any claims that may arise after the Effective Release Date. 

  
 2 

 In addition, nothing in this release of claims will be construed to affect any of the
following claims, all rights in respect of which are reserved: 
 (a)    Salary and employee benefits (to the extent of
my current participation and elections in such employee benefit plans) for my services as an employee through the Separation Date; 

(b)    Any payment or benefit set forth in Section 3 or 6 below; 

(c)    Claims in respect of my Base Options as provided in the Option Agreement and as amended by Section 5 below;

 (d)    Payment for repurchase of the Topco Shares set forth in Section 4 below; 

(e)    Reimbursement of unreimbursed business expenses properly incurred prior to the Separation Date in accordance with
Company policy; 
 (f)    Vested benefits under the employee benefit plans of the members of the Company Group (other
than severance pay or termination benefits, all rights to which are hereby waived and released); 
 (g)    Any claim
that the Company has breached this release of claims; and 
 (h)    Indemnification as a current or former officer or
director of the Company Group, including under Sections 21 and 22 of the Employment Agreement, or inclusion as a beneficiary of any insurance policy related to my service in such capacity. 

Without expanding the scope of the foregoing release, I understand and acknowledge that I am expressly waiving any and all rights under
Section 1542 of the Civil Code of the State of California, or any other federal or state statutory rights or rules or principles of common law or equity, or those of any jurisdiction, government, or political subdivision similar to
Section 1542 (“similar provision”) in effect as of the signing of this Agreement, and as a result, may not invoke the benefits of Section 1542 or any similar provision in order to prosecute or assert in any manner any claims that
are released under this release of claims. Section 1542 provides as follows: 
 “A general release does not extend to claims
that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released
party.” 
 I hereby represent that I have been paid all compensation owed and for all hours worked through the last regular payroll
date in May 2020 (but not yet for the remaining period of my employment from that date through the Separation Date), I have received all the leave and leave benefits and protections for which I am eligible, pursuant to the federal Family and Medical
Leave Act, the California Family Rights Act, any Company Group policy or applicable law, and I have not suffered any on-the-job injury or illness for which I have not
already filed a workers’ compensation claim. 

  
 3 

 I am not aware of any fraud or wrongdoing by any member of the Company Group and I have not
been retaliated against for reporting any allegations of fraud or other wrongdoing. 
 I confirm that I have no knowledge of any failure by
me or anyone else at the Company Group to have complied with any applicable legal or regulatory requirements or material policies or practices of the Company Group, which has not previously been reported to the Company’s Chief Compliance
Officer. Furthermore, I agree to notify the Company Group’s Chief Compliance Officer in the event that I become aware of any such compliance failure during the Severance Period (as defined below). 

I have been given 21 days to review this release of claims and have been given the opportunity to consult with legal counsel, and I am signing
this release of claims knowingly, voluntarily, and with full understanding of its terms and effects, and I voluntarily accept the severance payments and benefits provided for herein for the purpose of making full and final settlement of all claims
referred to above. If I have signed this release of claims prior to the expiration of the 21 day period, I have done so voluntarily. I also understand that I have seven (7) days after executing this release of claims to revoke it, and that this
release shall not become effective if I exercise my right to revoke my signature within seven (7) days of execution. I acknowledge and agree that any revocation of this release of claims must be in writing and received by the Company by the
close of business on the seventh (7th) day following my execution of this Agreement and shall be delivered to Chris Casler at Chris.Casler@agilonhealth.com, with a copy to Ravi Sachdev, on behalf
of the Board, at RSachdev@cdr-inc.com. If I elect to revoke this release of claims during the revocation period, this Agreement shall be void and of no effect in its entirety. However, I understand that the
termination of my employment shall still be effective. 
 No later than the Effective Release Date, I agree to return, or hereby represent
that, except as otherwise agreed to by a member of the Company Group, I have returned as of such date, to the Company all property of the Company Group, equipment and materials, including, but not limited to, any company vehicle, any laptop computer
and peripherals; any cell phone or other portable computing device; any telephone calling cards; keys; identification card; any credit or fuel cards; and all tangible written or graphic materials (and all copies) relating in any way to the Company
Group or its business, including, without limitations, documents, manuals, customer lists and reports, as well as all data contained on computer files, “thumb” drives, “cloud” services, or other data storage device, or home or
personal computers and/or e-mail or internet accounts. 
 2.    Transition
Period. For a 60 day period following the Separation Date (the “Transition Period”), the undersigned will assist the Company Group, as a non-employee consultant, in an orderly transition
of his former role, responsibilities and duties to his successor and other employees of the Company Group as directed by the Company’s Chief Executive Officer or the Board. If the undersigned incurs any reasonable
out-of-pocket expenses in 

  
 4 

 
connection with this transitional role, they will be paid for by the Company or reimbursed, subject to the terms of the Company’s reimbursement policy. The undersigned will not be paid any
additional fee or compensation for this assistance during the Transition Period. 
 3.    Severance. By reason of
the termination of the undersigned’s employment and subject to his execution and non-revocation of the general release of claims set forth in Section 1 above and his continued compliance with the
Restrictive Covenants (as defined below) as set forth in Section 8 below (the “Separation Benefit Conditions”): 

(a)    Cash Severance. The Company shall pay the undersigned severance equal to $2,625,000, which
shall be paid to him in equal installments over twenty-four (24) months on the Company’s normal payroll dates following the Separation Date (the “Severance Period”), except that the first installment of such payment shall
be paid on the 60th day following the Separation Date and shall include all installments that would have been paid to him if the release of claims provided herein had been effective on the
Separation Date, subject to the Company’s normal payroll practices and applicable withholding. 

(b)    Benefit Continuation. Provided that the undersigned properly has elected and is eligible to
receive continued health coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), during the first 18 months following the Separation Date, the Company shall provide him with continued medical,
dental and vision insurance coverage at active employee contribution rates with the Company reimbursing (or the Company otherwise bearing) the premium cost under COBRA in excess of the active-employee rate (the “Benefit
Continuation”). To receive reimbursements pursuant to this Section 3(b), the undersigned must promptly submit to the Company on a monthly basis documentation of his COBRA enrollment and monthly COBRA premium payment. In the event that
the undersigned obtains alternative employment during this coverage period and is eligible to obtain, and he obtains, medical coverage in connection therewith, his rights to the Benefit Continuation shall terminate. In the event that the Benefit
Continuation would subject him or the Company to a material cost, tax or penalty, the Company and the undersigned agrees to use commercially reasonable efforts to provide him with such benefits in a manner that does not trigger such tax, cost or
penalty, to the maximum extent possible. 
 (c)    No 2020 Bonus. No annual bonus shall be due to
the undersigned for 2020. 
 4.    Share Treatment. Within 90 days following the Separation Date, Topco will
repurchase from the undersigned all of his 15,000 Topco Shares for a total cash payment of $6,735,000, at a per share price of $449, and, upon his receipt of this payment and delivery of the Topco Shares to Topco, the undersigned will cease to be a
shareholder of Topco or have any rights in respect of the Topco Shares. As a condition to this repurchase, Topco and the undersigned shall enter into a stock repurchase agreement reflecting the foregoing terms, in the form customarily used by Topco
for repurchases of stock from former employees. 

  
 5 

 5.    Option Treatment. 

(a)    Provided that the undersigned has satisfied and complied with the Separation Benefit Conditions:

 (i)    as of the Separation Date, after giving effect to the undersigned’s termination of
employment without “cause”, all of the undersigned’s vested Base Options will be vested (i.e., 12,750 Base Options will become vested); 

(ii)    the exercise period applicable to each of the Base Options will be extended to its Normal
Termination Date (as defined in the Option Agreement), which is the 10th anniversary of its grant date (the “Extended Option Date”), and any Base Options that are not exercised on
or prior to the Extended Option Date, will terminate without consideration immediately thereafter; 

(iii)    in the event that Topco completes a Public Offering (as defined in the Amended and Restated Agilon
Health Topco, Inc. Stock Incentive Plan (the “Stock Incentive Plan”)) on or prior to the Extended Option Date, Topco will permit the undersigned to exercise, subject to the terms and conditions in the Option Agreement, (x) all
or any then outstanding Base Options on a cashless basis in the Public Offering and (y) after the Public Offering is completed and on or prior to the Extended Option Date, any then outstanding Base Options outstanding using a broker-assisted
cashless exercise program or same day sale; and 
 (iv)    in the event that the undersigned exercises
any Base Options prior to the Public Offering, neither he, Topco nor the CD&R Investor will have any rights to cause or obligations to participate in, a repurchase due to his termination of employment of any Option Shares acquired in any such
exercise. 
 (b)    All Upside Options will be unvested as of the Separation Date and therefore will be
automatically forfeited without any consideration as of the Separation Date. 
 6.    IPO/CIC Bonus. Provided
that the undersigned has satisfied and complied with the Separation Benefit Conditions, in the event a Public Offering with aggregate gross cash proceeds (without regard to any underwriting discount or commission) of at least $300 million or,
if approved by the CD&R Investor, a lower amount (whether to Topco, its stockholders, or both) or a Change in Control (as defined in the Stock Incentive Plan) is completed on or prior to December 31, 2021, the Company will pay the
undersigned $3,700,000 in a lump sum cash payment, no later than 30 days following completion of such Public Offering or Change in Control. 

  
 6 

 7.    Resignation. By the undersigned’s execution of this
Agreement, he hereby resigns (x) effective as of the date hereof, from all director positions with the Company Group and (y) effective as of the Separation Date, from all officer positions with the Company Group. From and after the
Separation Date, the undersigned shall no longer be authorized to conduct business on behalf of any member of the Company Group, including, but not limited, to entering into contracts on behalf of any member of the Company Group. The undersigned
agrees that, as requested by the Company from time to time, he will execute such other documents as may be necessary to evidence the resignations covered by this Agreement; provided that such documents shall not impose any new obligation or
waiver of rights by him that is not already contained in this Agreement. 
 8.    Restrictive Covenants. 

(a)    In consideration of the payments, benefits and equity treatment provided in this Agreement, the
undersigned acknowledges and agrees that the nonsolicitation, nondisparagement, confidentiality and other obligations that are included in Exhibit A to the Option Agreement to which he is a party will continue to apply to him after the Separation
Date for the periods set forth therein. In addition, (x) for 12 months following the Separation Date, the undersigned will not compete with the business of the Company Group as it is conducted on the Separation Date, which for purposes of this
Agreement shall mean partnering with physician practices to contract with Medicare Advantage health insurers under global risk contracts, but not owning or operating Medicare Advantage health plans or physician practices themselves, and
(y) without limiting the foregoing, during the nonsolicitation period, the undersigned will not directly or indirectly solicit or recruit [***]. 

(b)    The undersigned acknowledges and agrees that: the provisions of this Section 8 and Exhibit
A hereto (the “Restrictive Covenants”) do not impose an undue hardship on him and are not injurious to the public; these provisions are necessary to protect the business of the Company Group; the nature of his responsibilities
with the Company Group provided him with access to confidential or proprietary information or trade secrets that are valuable and confidential to the Company Group; the provisions of the Restrictive Covenants are reasonable in terms of length of
time and scope; and that adequate consideration supports the Restrictive Covenants. In the event that a court determines that the Restrictive Covenants or this Section 8 is unreasonably broad or extensive, the undersigned agrees that such court
should narrow such provision to the extent necessary to make it reasonable and enforce the provisions as narrowed. The Company Group reserves all rights to seek any and all remedies and damages permitted

  
 7 

 
under law, including, but not limited to, any remedies provided for pursuant to this Agreement and any other injunctive relief, equitable relief and compensatory damages for any breach of the
undersigned’s obligations under this Section 8. Without limiting the foregoing, if following the Separation Date, the undersigned materially breaches any of the Restrictive Covenants, the Company shall have no further payment or benefit
obligations under this Section 2 and Sections 5 and 6. 
 9.    Cooperation. Following the Separation Date,
the undersigned shall furnish such information and assistance to the Company Group as may be reasonably required by the Company in connection with any legal matters or litigation that may arise relating to issues or matters of which he had knowledge
of during his employment with the Company and its affiliates; provided, however, that the Company will use reasonable efforts to schedule such assistance at a mutually-convenient time prior to the end of the Severance Period and taking
into account his employment obligations and other activities at such time. 
 10.    Taxes. The undersigned shall
be solely responsible for all applicable taxes imposed on the undersigned by reason of any compensation or benefits provided under this Agreement (and, as applicable, the Option Agreement) and all such compensation and benefits shall be subject to
applicable federal, state and local withholding requirements. 
 11.     Confidential. Without limiting anything
to the contrary in this Agreement, except as required by law, the undersigned agrees not to disclose the terms hereof to any person or entity, other than the undersigned’s attorneys, accountants, financial advisors, or members of the
undersigned’s immediate family. Notwithstanding the foregoing, the undersigned may disclose the provisions of the Restrictive Covenants set forth in Section 8 above and in Exhibit A hereto to a prospective employer. 

12.    Governing Law, Jurisdiction ,etc. This Agreement shall be governed by and construed in accordance with the
laws of the State of Delaware without regard to its conflicts of law principles that would result in the application of another state’s laws. Each party to this Agreement irrevocably submits to the jurisdiction of deferral or state courts
located in the State of Delaware for any suit, action or other proceeding arising out of or relating to this Agreement, and hereby irrevocably agrees that all claims in respect of such suit, action or proceeding may be heard and determined in such
court. Each party to this Agreement hereby irrevocably waives, to the fullest extent that it may effectively do so, the defense of an inconvenient forum to the maintenance of such suit, action or other proceeding. The parties hereto further agree,
to the extent permitted by law, that final and unappealable judgment against any of them in any suit, action or other proceeding contemplated above shall be conclusive and may be enforced in any other jurisdiction within or outside the United States
by suit on the judgment, a certified copy of which shall be conclusive evidence of the fact and amount of such judgment. EACH PARTY TO THIS AGREEMENT HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL
BY JURY IN RESPECT OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. The parties hereto further agree to take any and all actions necessary or appropriate to effect this Section 12. 

  
 8 

 13.    Miscellaneous. This Agreement, together with the Option
Agreement and Subscription Agreement, constitutes the entire agreement and understanding between any member of the Company Group and the undersigned with respect to the subject matter hereof and supersedes all prior agreements and understandings
(whether written or oral) between the undersigned and any members of the Company Group relating to such subject matter, including the undersigned’s Employment Agreement (except for Sections 21 and 22 thereof). Its language shall be construed as
a whole, according to its fair meaning and not strictly for or against either party. Should any provision of this Agreement be declared or determined by any court to be illegal or invalid as a result of any action or proceeding, the validity of the
remaining parts, terms, or provisions shall not be affected thereby and any said illegal or invalid part, term or provision shall be deemed not to be a part of this Agreement. This Agreement may be executed in counterparts (including via facsimile
or .pdf file). 
 [Signature Page Follows] 

  
 9 

 IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto as of the first
date written below. 
  

			
	 EXECUTIVE

	
	 /s/ Ronald J. Kuerbitz

	Name: Ronald J. Kuerbitz

  

	
	AGILON HEALTH HOLDINGS, INC.
	
	 /s/ Ravi Sachdev

	By: Ravi Sachdev
	Title: President

  

	
	 Solely for purposes of Sections 4 and 5 above:

	
	 AGILON HEALTH TOPCO, INC.

	
	 /s/ Ravi Sachdev

	 By: Ravi Sachdev

	 Title: President

 

	
	CD&R VECTOR HOLDINGS, L.P.
	
	By: CD&R Investment Associates IX, Ltd., its general partner
	
	 /s/ Theresa A. Gore

	By: Theresa A. Gore
	Title: Chief Financial Officer, Treasurer &
	Secretary

 Exhibit A 

Restrictive Covenants 

[see attached] 

 Exhibit A 

Restrictive Covenants 

Section 1 Confidential Information. 

1.1 The Employee agrees that during the Employee’s employment with the Company, and thereafter, the Employee will not disclose
confidential or proprietary information, or trade secrets, related to any business of the Company, the Subsidiaries or any of their respective Affiliates, including without limitation, and whether or not such information is specifically designated
as confidential or proprietary: all business plans and marketing strategies; information concerning existing and prospective markets, suppliers and customers; financial information; information concerning the development of new products and
services; and technical and non-technical data related to software programs, design, specifications, compilations, inventions, improvements, patent applications, studies, research, methods, devices,
prototypes, processes, procedures and techniques (collectively, “Confidential Information”). Subject to Section 2 of this Exhibit A, the Employee agrees to hold as Company property all Confidential Information and all books,
papers, media and other data and all copies thereof and therefrom, in any way relating to the businesses of the Company, the Subsidiaries or any of their respective Affiliates, whether made or received by the Employee. “Confidential
Information” does not include information that is or becomes generally known to the public, other than through the breach of this Exhibit A by the Employee. 

1.2 Notwithstanding anything herein to the contrary, this Agreement does not prohibit the Employee from disclosing Confidential Information to
the extent required by applicable law, providing truthful testimony or accurate information in connection with any investigation being conducted into the business or operations of the Company by any government agency or other regulator that is
responsible for enforcing a law on behalf of the government or otherwise providing information to the appropriate government regulatory agency or body regarding conduct or action undertaken or omitted to be taken by the Company that the Employee
reasonably believes is illegal or in material non-compliance with any financial disclosure or other regulatory requirement applicable to the Company. 

1.3 The Employee hereby assigns to the Company any rights the Employee may have or acquire in such Confidential Information and acknowledges
that all Confidential Information shall be the sole property of the Company, the Subsidiaries and/or their respective Affiliates or their assigns. 

  
 15 

 1.4 The Employee’s obligations under this Section 1 are indefinite in term. 

Section 2 Return of Company Property. The Employee acknowledges that all tangible items containing any Confidential Information or
trade secrets, including, without limitation, memoranda, photographs, records, reports, manuals, drawings, blueprints, prototypes, notes, documents, drawings, specifications, software, media and other materials, including any copies thereof
(including electronically-recorded copies), are the exclusive property of the Company and the Subsidiaries, and the Employee shall deliver to the Company all such material in the Employee’s possession or control upon the Company’s request
and in any event upon the termination of the Employee’s employment with the Company. The Employee shall also return any keys, equipment, identification or credit cards, or other property belonging to the Company or its Subsidiaries upon
termination of the Employee’s employment or the Company’s request. 
 Section 3 Nonsolicitation. The Employee hereby
covenants and agrees that, during the Employee’s employment with the Company and for the two-year period following the date on which the Employee’s employment with the Company terminates for any
reason, the Employee shall not, directly or indirectly, as an employee, agent, consultant, partner, joint venture, owner, officer, director, member of any other firm, partnership, corporation or other entity or in any other capacity, directly or
indirectly: 
 (a) solicit, induce or encourage any then-current employee of the Company, any Subsidiary or any of the
Company’s Affiliates to leave their employment with the Company, the Subsidiaries or any of the Company’s Affiliates; and 

(b) (i) induce (or attempt to induce) a breach or disruption of the contractual relationship between the Company,
any Subsidiary or any of the Company’s Affiliates and any physician, who is then-currently, either directly or through an independent physician association, under contract with the Company, any Subsidiary or any of the Company’s
Affiliates, or who was, either directly or through an independent physician association, under contract with the Company or any of its Affiliates in the prior one-year period (any such physician, a
“Restricted Physician”) or (ii) use Confidential Information or the trade secrets of the Company or any of its Affiliates to solicit, induce or encourage any Restricted Physician to end his or her relationship with the Company
or any of its Affiliates, as applicable. 

  
 16 

 Section 4 Intellectual Property. 

4.1 The Employee shall at all times during the Employee’s employment with the Company and thereafter (i) fully and promptly
disclose to the appropriate Company personnel any Developments (as defined below) that the Employee becomes aware of or involved in, (ii) make himself or herself generally and reasonably available to Company representatives to discuss
such Developments; and (iii) hold all Developments for the sole use and benefit of the Company. 
 4.2 As used herein,
“Developments” shall mean any and all work product, and the intellectual property rights therein, made, conceived, created, discovered, authored, invented, developed or reduced to practice (collectively, “Created”)
by the Employee during and within the scope of the Employee’s employment with the Company (including actual and/or anticipated business, developments, inventions or research), whether Created by the Employee alone or working with others,
whether or not such items are patentable, registrable, or protected as Confidential Information or trade secrets, whether or not made or conceived during normal working hours or on the Company’s premises, or protected as Confidential
Information or trade secrets, including but not limited to inventions, ideas, improvements, modifications, discoveries, know-how, creations, designs, technologies, techniques, devices, formulae, software,
models, trademarks, patents, service marks, copyrights, copyrightable material, works of authorship, trade secrets, methods, processes, developments, derivatives, mask works, works made for hire, rights of priority, reissue of letters patent,
renewals, registrations and extensions that are at any time granted with respect to any one or more of the foregoing intellectual property items. For the avoidance of doubt, “Developments” do not include any intellectual property Created
by the Employee prior to the commencement of his or her employment with the Company (unless otherwise agreed with the Company or its Affiliates). 

4.3 Notice required by the State of California and any other state requiring such notice: The Employee understands that the
Employee’s obligation to assign inventions to the Company under this Section 4 shall not apply to any inventions for which no equipment, supplies, facilities, or trade secret information of the Company or its Affiliates was used and that
was developed entirely on the Employee’s own time, unless (i) the invention relates directly to the business of the Company, or to the Company’s actual or demonstrably anticipated research or development or (ii) the
invention results from any work performed by the Employee for the Company. 
 4.4 The Employee acknowledges and agrees that any copyrightable
works included in the Developments are “works-made-for- hire” under the U.S. Copyright Act of 1976 (as amended) and the copyright laws of other relevant
jurisdictions and that the Company will be considered the author and owner of such copyrightable works. The Employee hereby irrevocably assigns, transfers, 

  
 17 

 
conveys, and delivers to the Company all of the Employee’s right, title and interest in and to the Developments. The Employee understands and acknowledges that the Developments include, and
the assignment in this Section 4 constitutes a present conveyance to the Company of ownership of, property and rights in existence as of or prior to the date of this Agreement, those currently being Created, as well as those which have not yet
been Created. 
 4.5 The Employee hereby irrevocably assigns, transfers, conveys, and delivers to the Company, and waives and agrees never to
assert, any and all Moral Rights (defined below) that the Employee may have in or with respect to any Developments, even after termination of Employee’s employment with the Company. As used herein, “Moral Rights” mean any
rights to claim authorship of any Development, to object to or prevent any modification of any Development, to withdraw from circulation or control the publication or distribution of any Development, and any similar right existing under any law
anywhere in the world. 
 4.6 The Employee agrees at all times during the Employee’s employment with the Company and thereafter to sign
and deliver any and all further documents necessary or desirable to effectuate or evidence the assignments and waivers set forth in this Section 4 and to maintain, perfect, and enforce patent, copyright, trade secret and other legal protection
for the Developments. 
 4.7 The Employee shall not use any of the Developments or any Residual Knowledge (defined below) related to the
Developments for any purpose unrelated to the Employee’s duties at the Company during and after termination of Employee’s employment with the Company. As used herein, “Residual Knowledge” means any information or idea known to
and remembered by Employee without the use of or reliance on any materials or other tangible objects containing such information or idea. 

4.8 If, in the course of providing services to the Company, the Employee exploits or incorporates into any Developments any work product, or
intellectual property rights therein, owned by the Employee or in which the Employee has an interest (“Employee IP”), the Employee hereby grants to the Company a nonexclusive, royalty-free, perpetual, irrevocable, worldwide right and
license to make, have made, copy, modify, use, distribute, sell or otherwise exploit such Employee IP in the conduct of the Company’s and its Affiliates’ business. 

Section 5 Nondisparagement. Except to the extent it would violate applicable law, while employed by the Company and thereafter,
the Employee shall not, whether in writing or orally, disparage the Company, any Subsidiary, their respective Affiliates or their respective predecessors and successors, or any of the current or former directors, officers, employees, shareholders,
partners, 

  
 18 

 
members, agents or representatives of any of the foregoing, with respect to any of their respective past or present activities; or otherwise publish (whether in writing or orally) statements that
tend to portray any of the aforementioned parties in an unfavorable light; provided that nothing herein shall or shall be deemed to prevent or impair the Employee from (x) testifying truthfully in any legal or administrative proceeding
if such testimony is compelled or requested (or otherwise complying with legal requirements) or (y) responding to a public disparaging statement by Parent, the Company or any of their respective executive officers or directors. Except to
the extent it would violate applicable law, while employed by the Company and thereafter, Parent and the Company shall not, and shall instruct their officers and directors not to, whether in writing or orally, disparage the Executive with respect to
any of his past or present activities; or otherwise publish (whether in writing or orally) statements that tend to portray the Executive in an unfavorable light; provided that it shall not be a violation of this Section 5 for Parent, the
Company or any of their respective executive officers or directors to make reasonable, customary or other appropriate public remarks as to the performance of the Company Group with respect to periods that include the period of the Employee’s
employment; provided, further, that nothing herein shall or shall be deemed to prevent or impair any of Parent, the Company or their respective executive officers or directors from (X) testifying truthfully in any legal or
administrative proceeding if such testimony is compelled or requested (or otherwise complying with legal requirements) or (y) responding to a public disparaging statement by the Employee. 

Section 6 Remedies. The Company and the Employee agree that the provisions of this Exhibit A do not impose an undue hardship on
the Employee and are not injurious to the public; that these provisions are necessary to protect the business of the Company, the Subsidiaries and the Company’s Affiliates; that the nature of the Employee’s responsibilities with the
Company provide and/or will provide the Employee with access to confidential or proprietary information or trade secrets that are valuable and confidential to the Company, the Subsidiaries and the Company’s Affiliates; that the Company would
not grant Options to the Employee if the Employee did not agree to the provisions of this Exhibit A; that the provisions of this Exhibit A are reasonable in terms of length of time and scope; and that adequate consideration supports the provisions
of this Exhibit A. In the event that a court determines that any provision of this Exhibit A is unreasonably broad or extensive, the Employee agrees that such court should narrow such provision to the extent necessary to make it reasonable and
enforce the provisions as narrowed. The Company reserves all rights to seek any and all remedies and damages permitted under law, including, but not limited to, any remedies provided for pursuant to the provisions of the Plan and related Award
Agreements and any other injunctive relief, equitable relief and compensatory damages for any breach of the Employee’s obligations under this Exhibit A. 

  
 19 

 Section 7 Miscellaneous. The Employee’s obligations under this Exhibit A
shall be cumulative of any similar obligations the Employee has under any other agreement with the Company, any Subsidiary or any of their respective Affiliates. 

  
 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]